Naurex Spinout Aptinyx Launches After Allergan Deal

Work did not slow down at Naurex after its acquisition by Allergan for $560m up front – a return of at least 3.4 times the $163m in venture capital invested in the company – since the underlying technology platform was spun out in a new firm, which launched on Sept. 16 as Aptinyx.

More from Neurological

More from Therapy Areas